Showing results (51-60 of 143) with videos related to
Sort By:
Pageof 15
British Journal of Clinical Pharmacology|January 9, 2020
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in VigibaseJustine Perino, Nathan Mottal, Yohann Bohbot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid LeukemiaOlga Salamero, Pau Montesinos, Christophe Willekens, et al.American Journal of Hematology|April 17, 2021
Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Laure Philippe Walter, Lucile Couronné, Jean-Philippe Jais, et al.Scientific Reports|June 13, 2022
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AMLEmmanuel Gyan, Arnaud Pigneux, Mathilde Hunault, et al.Leukemia Research|May 30, 2008
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA groupOumedaly Reman, Arnaud Pigneux, Françoise Huguet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.Cancer|April 8, 2015
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL groupThorsten Braun, Sophie Cereja, Sylvie Chevret, et al.Blood Advances|September 15, 2021
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO studyRaynier Devillier, Edouard Forcade, Alice Garnier, et al.Bone Marrow Transplantation|October 21, 2023
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapyGérard Socié, Pere Barba, Arie Barlev, et al.Pageof 15